The new memos from the Food and Drug Administration show how the agency’s vaccine chief, Dr. Vinay Prasad, personally ...

Moderna stock popped Wednesday after the CDC recommended the company's RSV vaccine for at-risk adults in their 50s.

Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...

Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are ...

Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to ...

Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include adults aged 18 to 59 who are at high risk of severe illness if they ...

Moderna said the approval was supported by a study showing the vaccine is safe and works well for younger adults (ages 18 to 59) with medical conditions. Their immune response was just as strong ...

The vaccine was previously only licensed for adults aged 60 years and older. “RSV poses a serious health risk to adults with certain chronic conditions, and today’s approval marks an important step ...

The vaccine was previously only licensed for adults aged 60 years and older. “RSV poses a serious health risk to adults with certain chronic conditions, and today’s approval marks an important step ...